PLETAL

This brand name is authorized in Germany, Turkey, United Kingdom

Active ingredients

The drug PLETAL contains one active pharmaceutical ingredient (API):

1 Cilostazol UNII N7Z035406B - CILOSTAZOL

Cilostazol and several of its metabolites are phosphodiesterase III inhibitors which suppress cyclic AMP degradation, resulting in increased cAMP in a variety of tissues including platelets and blood vessels. Studies in animals and in man (in vivo and ex vivo) have shown that cilostazol causes reversible inhibition of platelet aggregation. Read about Cilostazol

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
PLETAL Tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
B01AC23		B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AC Platelet aggregation inhibitors excl. heparin
Discover more medicines within B01AC23

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: DE	Bundesinstitut für Arzneimittel und Medizinprodukte	Identifier(s): 07751809, 07751815, 07751821, 08875620, 08875643, 11296452, 11296469, 11296475, 12359166
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 178847, 180656, 186060, 373618
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8680683010095, 8680683010101, 8680683010118, 8680683010125